← ANALYST RATINGS · TIPRANKS

Liquidia Technologies (LQDA): analyst forecast and price target

$34.35 −1.24% close 16.10.26 · market cap $3.1B · Healthcare · Medical - Pharmaceuticals IWM 0.08%
Price targets and ratings of

Analyst consensus

Strong Buy

6 Buy2 Hold0 Sell

Ratings of 8 analysts in the last 3 months

12-month forecast

$53.12+54.7% upside

Based on 8 price targets given in the last 3 months, the average target is $53.12, the highest $70.00, the lowest $33.00. The average is +54.7% from the last price of $34.35.

$20.00$40.00$60.00$80.00Jan 26AprJulOctJan 27AprJulOctHigh$70.00Average$53.12Low$33.00
Highest target $70.00 Average target $53.12 Lowest target $33.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% H.C. Wainwright $58.00 → $65.00+12.1% Buy +89.2% Reiterated 15.10.26on TipRanks 06:20 +2.2%next day −0.1%
Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% Bank of America Securities $38.00 → $42.00+10.5% Hold +22.3% Reiterated 14.10.26on TipRanks Oct 15 05:30 +27.7%next day +2.2%
Gaurav Maini★★★★★★★★★★#2199 · hits 88% · avg +29.5% LifeSci Capital $90.00 → $59.00−34.4% Buy +71.8% Upgrade 14.10.26on TipRanks 07:40 +27.7%next day +2.2%
Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% Needham $72.00 → $58.00−19.4% Buy +68.9% Reiterated 14.10.26on TipRanks 07:30 +27.7%next day +2.2%
Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% BTIG $111 → $70.00−36.9% Buy +103.8% Upgrade 14.10.26on TipRanks 06:10 +27.7%next day +2.2%
Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% Wells Fargo $30.00 → $33.00+10.0% Hold −3.9% Reiterated 13.10.26on TipRanks Oct 14 05:50 −3.1%next day +27.7%
Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% Bank of America Securities $40.00 → $38.00−5.0% Hold +10.6% Reiterated 09.10.26on TipRanks 06:55 −2.9%next day +1.1% · 5 days +27.4%
Amy Li★★★★★★★★★★#5687 · hits 36% · avg +7.6% Jefferies $45.00 Buy +31.0% Reiterated 05.10.26on TipRanks 09:55 −4.2%next day −6.8% · 5 days −0.3%
Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% H.C. Wainwright $130 → $58.00−55.4% Buy +68.9% Reiterated 02.10.26on TipRanks 06:20 +1.6%next day −4.2% · 5 days −5.6%
Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% Wells Fargo $108 → $30.00−72.2% Hold −12.7% Downgrade 01.10.26on TipRanks Oct 2 05:50 −7.7%next day +1.6% · 5 days −1.2%
Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% Bank of America Securities — Hold — Reiterated 01.10.26on TipRanks 11:07 −7.7%next day +1.6% · 5 days −1.2%
Amy Li★★★★★★★★★★#5687 · hits 36% · avg +7.6% Jefferies $45.00 Buy +31.0% Reiterated 01.10.26on TipRanks 10:25 −7.7%next day +1.6% · 5 days −1.2%
Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% BTIG — Hold — Downgrade 01.10.26on TipRanks 07:30 −7.7%next day +1.6% · 5 days −1.2%
Gaurav Maini★★★★★★★★★★#2199 · hits 88% · avg +29.5% LifeSci Capital — Hold — Reiterated 30.09.26on TipRanks 18:25 −7.7%next day +1.6% · 5 days −1.2%
Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% Needham $110 → $72.00−34.5% Buy +109.6% Reiterated 30.09.26on TipRanks 15:45 −57.0%next day −7.7% · 5 days −13.7%
Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% Raymond James $106 → $53.00−50.0% Buy +54.3% Reiterated 30.09.26on TipRanks 14:15 −57.0%next day −7.7% · 5 days −13.7%
Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% Wells Fargo $108 Buy +214.4% Reiterated 08.09.26on TipRanks Sep 9 05:50 −0.9%next day +2.6% · 5 days −1.8%
Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% H.C. Wainwright $130 Buy +278.5% Reiterated 14.08.26on TipRanks Aug 13 11:45 −9.2%next day +3.4% · 5 days +0.5%
Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% Bank of America Securities $79.00 → $92.00+16.5% Hold +167.8% Reiterated 12.08.26on TipRanks Aug 13 06:50 −10.8%next day −9.2% · 5 days −3.9%
Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% BTIG $109 → $111+1.8% Buy +223.1% Reiterated 12.08.26on TipRanks Aug 13 06:25 −10.8%next day −9.2% · 5 days −3.9%
Amy Li★★★★★★★★★★#5687 · hits 36% · avg +7.6% Jefferies $57.00 → $60.00+5.3% Buy +74.7% Assigned 11.05.26on TipRanks 15:25 +25.4%next day +6.7% · 5 days +7.3%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Liquidia Technologies

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Serge Belanger★★★★★★★★★★Needham · #674
Hits 49%244 of 503 Average return +14.9%
1 year Julian Harrison★★★★★★★★★★BTIG · #42
Hits 57%246 of 430 Average return +53.4%
2 years Serge Belanger★★★★★★★★★★Needham · #674
Hits 49%244 of 503 Average return +14.9%

Most profitable

3 months Serge Belanger★★★★★★★★★★Needham · #674
Hits 49%244 of 503 Average return +14.9%
1 year Julian Harrison★★★★★★★★★★BTIG · #42
Hits 57%246 of 430 Average return +53.4%
2 years Serge Belanger★★★★★★★★★★Needham · #674
Hits 49%244 of 503 Average return +14.9%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $81.20 at a price of $30.26 (+168.3%); now: $53.12 at $34.35 (+54.7%).

$40.00$60.00$80.00Sep 15Oct 1Oct 15Top analysts$57.60Average target$53.12Price$34.35

PriceAverage targetTop analysts’ target

Recommendation trend

01020145Oct 25151Nov142Dec74Jan 2614Feb561Mar551Apr41411May162Jun1172Jul2133Aug583Sep1259Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy4012512
Buy1416171385
Hold122339
Sell100000

Earnings and sales forecast

Next report: 10.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.92 (from $0.66 to $1.24). Last quarter: $0.74.

Sales

Next quarter’s sales estimate — $214M (from $181M to $226M). Last quarter: $172M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Liquidia Technologies
  • CEO: Roger A. Jeffs
  • Employees: 216
  • 419 Davis Drive, Morrisville, NC, 27560, US
  • www.liquidia.com

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Data from the stock’s TipRanks forecast page, read 47 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗